Analyst Price Targets — GHRS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 19, 2026 10:03 am | — | H.C. Wainwright | $65.00 | $21.68 | TheFly | GH Research price target lowered to $65 from $70 at H.C. Wainwright |
| May 15, 2026 11:57 am | — | Cantor Fitzgerald | $35.00 | $21.18 | TheFly | GH Research price target raised to $35 from $25 at Cantor Fitzgerald |
| March 10, 2026 10:40 am | Eddie Hickman | Guggenheim | $34.00 | $15.81 | StreetInsider | GH Research PLC (GHRS) PT Raised to $34 at Guggenheim |
| March 6, 2026 12:04 pm | Ami Fadia | Needham | $32.00 | $15.34 | StreetInsider | GH Research PLC (GHRS) PT Raised to $32 at Needham |
| January 23, 2026 7:24 pm | — | RBC Capital | $40.00 | $16.73 | TheFly | GH Research price target raised to $40 from $33 at RBC Capital |
| January 6, 2026 12:40 pm | — | Needham | $29.00 | $15.46 | TheFly | GH Research price target raised to $29 from $19 at Needham |
| January 6, 2026 11:24 am | — | Canaccord Genuity | $39.00 | $15.46 | TheFly | GH Research price target raised to $39 from $35 at Canaccord |
| January 6, 2026 10:05 am | — | Wolfe Research | $39.00 | $15.46 | StreetInsider | GH Research (GHRS) Reiterated at Market Outperform by Citizens on GH001 Potential |
| January 5, 2026 2:59 pm | Eddie Hickman | Guggenheim | $29.00 | $15.80 | StreetInsider | Guggenheim Reiterates Buy Rating on GH Research PLC (GHRS) Post Mgmt Call |
| November 10, 2025 4:07 pm | Patrick Trucchio | H.C. Wainwright | $35.00 | $13.55 | TheFly | GH Research price target lowered to $35 from $40 at H.C. Wainwright |
Latest News for GHRS
GH Research PLC (NASDAQ:GHRS) and Definium Therapeutics Inc. (NASDAQ:DFTX) stocks are trading higher in response to Eli Lilly and Co. (NYSE:LLY) agreeing to acquire AtaiBeckley Inc. (NASDAQ:ATAI) in a deal valued at up to $3.80 billion.
CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...
Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...
The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Jefferies said could benefit companies including Compass Pathways (NASDAQ:CMPS), AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Cybin Inc. (NYSE-A:CYBN, FRA:R7E), GH Research (NASDAQ:GHRS), Awakn Life Sciences (NEO:AWKN) and…
DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral presentations at the 37th World Congress of Neuropsychopharmacology (CINP 2026). The peer-reviewed article, titled “Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression: A Phase 2a…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GHRS.
U.S. House Trading
No House trades found for GHRS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.